POU5F1 (POU Class 5 Homeobox 1)

In addition to technical validation, we describe a practical approach to optimize the manufacturing workflow to improve operational efficiency within clinical environments. These included predefined process pauses to manage personnel and expiration-prone materials, thereby enhancing the feasibility and reproducibility of iPSC manufacturing in real-world GMP-compliant work environments.

Collectively, this study elucidated the molecular characteristics of ovarian tissue transcription during early gestation, thereby facilitating further investigation into genetic markers and gene regulatory networks associated with ovarian development. This may provide valuable insights for research on reproductive disorders and genetic breeding.

In CSC-enriched cells, SATB2 inhibition was associated with increased sensitivity to cisplatin and pemetrexed, concomitant with reduced OCT4 and SOX2 expression. Collectively, these findings support SATB2 as a candidate therapeutic target in MPM and suggest that SATB2 suppression may enhance chemotherapy response when combined with standard agents.

Multicellular spheroids were separately transfected with siRNA, EXO-siRNA and, treated with cisplatin alone...However, the reduction of LGR5 expression via siRNA led to a marked decrease in SOX9 and OCT4 levels, while NANOG expression remained largely unchanged. In summary, the results indicated that LGR5 suppression is effective in reducing stemness-related genes and may be considered a good candidate for combination therapy along with chemotherapy.

Our findings demonstrate that GDF15 acts as a tumor promoter in CRC by driving EMT, facilitating proliferation and metastasis, and enhancing cancer stemness. This study identifies GDF15 as a potential biomarker and therapeutic target for CRC.

Pan-cancer analysis revealed the potential of ZNF184 as a prognostic and predictive biomarker for adverse clinical outcomes. Collectively, these findings reveal a previously unknown role of ZNF184 in breast cancer progression and paclitaxel resistance, providing new insights into ZNF184 as a potential therapeutic target for cancer patients.

These results support the existence of PGC-like cells that within the normal pituitary gland. This study provides new insights into the cellular origins of iGCTs and suggests further investigation into the regulatory mechanisms that may lead to tumorigenesis.

PLCXD3 functions as a tumor suppressor in gastric cancer by inhibiting cell migration, invasion, and stemness through modulation of the Wnt/β-catenin pathway. Its downregulation may serve as a novel early diagnostic biomarker and a promising therapeutic target in gastric cancer management.

Notably, Dynorphin A disrupted zinc finger E-box binding homeobox 1 (ZEB1)-mediated Wnt/β-catenin signaling, and forced expression of ZEB1 partially rescued β-catenin levels, confirming that ZEB1 is a downstream mediator. These findings identify Dynorphin A as a promising endogenous inhibitor of TNBC progression that targets both malignancy and stemness via the ZEB1/β-catenin axis.

Mechanistically, USP30-AS1 acts as a competing endogenous RNA (ceRNA) by sponging miR-3646, which leads to the derepression of Frizzled-7 (FZD7) and subsequent activation of the Wnt/β-catenin signaling pathway. These findings identify USP30-AS1 as a critical promoter of stemness, chemoresistance, and metastasis in BCSCs via the miR-3646/FZD7/Wnt axis, suggesting it is a potential therapeutic target for breast cancer intervention.

Extending to differentiation, integrin-ECM crosstalk directs lineage commitment across diverse fates, including hematopoietic, cardiovascular, neural, hepatic, epithelial, endodermal, and oligodendroglial lineages, by fine-tuning signaling specificity and ECM composition. This review focuses on recent advances in the mechanistic interplay between integrin signaling and ECM proteins in hPSC maintenance, mechanotransduction, and lineage-directed differentiation, emphasizing defined culture systems and their translational potential in regenerative medicine.

The findings highlight GD's potential as a promising therapeutic candidate for PDAC, with the ability to target both bulk tumor cells and PCSCs. By simultaneously suppressing tumor growth, stemness, and metastatic spread, GD may contribute to more effective treatment strategies and improved patient outcomes.